Skip to content

XBIO REPORT

FREE WEEKLY BIOTECH STOCK CATALYST REPORTS
CONTACT

Tag: Mount Sinai

October 26, 2026

A Breakthrough in Endometrial Cancer: New Chemotherapy-Free Treatment Shows Promise

A Shift in Cancer Care A landmark global Phase 3 clinical trial, led by a physician at Mount Sinai Medical Center, has unveiled encouraging results for patients with dMMR (mismatch repair deficient) endometrial cancer. The study demonstrates that a chemotherapy-free treatment regimen can significantly improve outcomes, marking a potential turning point in how this gynecological…

Announcements

Clinical Trial, dMMR, Endometrial Cancer, Mount Sinai, oncology, pr-newswire
April 18, 2026

Advancing Oncology: Mount Sinai Health System Partners with SOPHiA GENETICS to Elevate Precision Cancer Care

NASDAQ: $SOPH In a significant move for the future of precision medicine, the Mount Sinai Health System has announced a strategic collaboration with SOPHiA GENETICS. This partnership marks a new chapter for one of the nation’s most prestigious academic health systems, as it integrates the AI-powered SOPHiA DDM™ Platform to refine its genomic testing capabilities…

Announcements

$SOPH, Genomics, Mount Sinai, oncology, precision medicine, SOPHiA GENETICS

© XBioReport.com

Disclaimer: This site is for information only. Not investment advice.

Buy A Premium Report To Maximize Your Returns

The FREE bio tech stock catalyst report ONLY includes companies with catalysts within the current week. Often, this may not be enough time to capture the pre-catalyst stock price movements. For MAX RETURNS, buy a premium report below with longer outlooks, allowing you to discover earlier trade entries. Get positioned BEFORE a price move happens. Don’t miss out, maximize your return potential!

Choose your outlook window (each priced accordingly)

Get FREE Biotech Stock Catalyst Reports

Email